Chronic Myeloid Leukemia

BCR-ABL transcripts can show residual disease after treatment

Published in Blood Weekly, April 25th, 2002

by Michael Greer, senior medical writer - Levels of the BCR-ABL oncogene estimated by polymerase chain reaction (PCR) analysis can show residual disease in chronic myeloid leukemia (CML) patients, researchers in Brazil report.

Dr. Ivone B. Otazu and colleagues at the National Cancer Institute in Rio de Janeiro and the Federal University of Rio de Janeiro examined the utility of BCR-ABL measurement after bone marrow transplantation.

Quantitative PCR was highly useful for detecting minimal residual disease in the form of BCR-ABL transcripts, Otazu and coauthors found.

They measured levels of the oncogene in a total of 39 CML...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-04-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry